Jennelle C. Hodge

Jennelle C. Hodge

Auto-generated profile, based on publicly available information

Jennelle C. Hodge

Department of Medical and Molecular Genetics, and IU Simon Comprehensive Cancer Center, Indiana University, Indianapolis, Indiana, USA

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 February 2026 in Histopathology
Verified
Journal Article
Open access
MAMark Johan Arends
Mark Johan Arends
Irene EspositoIrene Esposito
Irene Esposito
AGAnthony J Gill
Anthony J Gill
RHRalph Hruban
Ralph Hruban
Joseph KhouryJoseph Khoury
Joseph Khoury
INIris D. Nagtegaal
Iris D. Nagtegaal
The 6th Edition of the WHO Classification of Digestive System Tumours represents a significant update to the 5th edition. It integrates pathological, new molecular, and clinical insights to refine the taxonomy of digestive system neoplasms. The revised classification continues to emphasise standardisation in terminology, coding, and diagnostic criteria to facilitate global consistency in diagnosis, treatment, epidemiological reporting and research. Structural reorganisation of book chapters describes epithelial tumours by anatomical site, while separating neuroendocrine, mesenchymal and haematolymphoid tumours into dedicated chapters that are aligned with other WHO tumour volumes. Genetic tumour syndromes are classified by mechanisms, pathways and genes, whereas metastatic disease is comprehensively covered under other tumours and metastases. Key structural and diagnostic refinements include consolidation of gastric dysplasia entities; separation of duodenal/ampullary from jejuno‐ileal tumours; clearer categorisation of colorectal serrated polyps and novel carcinoma grading; introduction of small‐ and large‐duct intrahepatic cholangiocarcinoma as separate entities, and redefinition of undifferentiated carcinoma to include ‘carcinoma with mesenchymal differentiation’. Several new entities are introduced, including oesophageal epidermoid metaplasia, colorectal intramucosal adenocarcinoma, low‐grade tubuloglandular adenocarcinoma and lymphoglandular complex‐like adenocarcinoma, intraductal tubulopapillary and intraductal oncocytic papillary neoplasms of the bile ducts and sonic hedgehog hepatocellular adenoma. The concept of amphicrine‐like carcinoma (ALC) is distinguished from MiNEN and broadens the understanding of tumours with dual neuroendocrine–non‐neuroendocrine differentiation. Grading systems are simplified to two‐tier classifications (low/high grade) across precursor lesions, with enhanced criteria for neuroendocrine tumour grading. Anal canal neoplasia terminology is harmonised with human papillomavirus (HPV) related Lower Anogenital Squamous Terminology (LAST) and mass‐forming biliary and gallbladder cancer precursors share similar terminology. Finally, carcinoma of unknown primary (CUP) is included in a separate section for the first time, classified by molecular and immunophenotypic profiles to guide therapy. Overall, the 6th edition strengthens tumour diagnostic precision and molecular alignment across the digestive system.

20 November 2025 in Histopathology
Verified
Journal Article
Open access
GGGabrielle Goldman‐Lévy
Gabrielle Goldman‐Lévy
Raymond BarnhillRaymond Barnhill
Raymond Barnhill
BBBoris C. Bastian
Boris C. Bastian
Werner KempfWerner Kempf
Werner Kempf
DEDavid Elder
David Elder
DLDilani Lokuhetty
Dilani Lokuhetty
The 5th edition of the World Health Organization Classification of Tumours (WCT) serves as a foundation for global diagnostic standards in tumour pathology. Similar to other volumes in this series, the Skin Tumours (Skin5) edition follows a standardized approach. This edition introduces two new chapters: ‘Tumours of the nail unit’ and ‘Metastases to skin’, along with new entities across relevant chapters. This review article provides an overview of the updates in Skin5 based on currently published evidence, with emphasis on newly introduced chapters and newly described entities that involve the skin, in particular, epidermal, melanocytic and appendageal tumours.

1 December 2012 in Archives of General Psychiatry
Verified
Journal Article
Open access
PDF file
CECarl Ernst
Carl Ernst
CMChristian R Marshall
Christian R Marshall
YSYiping Shen
Yiping Shen
KMKay Metcalfe
Kay Metcalfe
JRJill Rosenfeld
Jill Rosenfeld
MTMichael E Talkowski
Michael E Talkowski
Assessment blood consumption and trauma-associated severe hemorrhage scores are useful for predicting the need for massive transfusion (MT) in severe traum

21 August 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
TSTyler Shugg
Tyler Shugg
ETEmma M Tillman
Emma M Tillman
ABAmy M. Breman
Amy M. Breman
JHJennelle C. Hodge
Jennelle C. Hodge
CMChristine A. McDonald
Christine A. McDonald
TSTodd Skaar
Todd Skaar
In 2019, Indiana University launched the Precision Health Initiative to enhance the institutional adoption of precision medicine, including pharmacogenetics (PGx) implementation, at university‐affiliated practice sites across Indiana. The overarching goal of this PGx implementation program was to facilitate the sustainable adoption of genotype‐guided prescribing into routine clinical care. To accomplish this goal, we pursued the following specific objectives: (i) to integrate PGx testing into existing healthcare system processes; (ii) to implement drug–gene pairs with high‐level evidence and educate providers and pharmacists on established clinical management recommendations; (iii) to engage key stakeholders, including patients to optimize the return of results for PGx testing; (iv) to reduce health disparities through the targeted inclusion of underrepresented populations; (v) and to track third‐party reimbursement. This tutorial details our multifaceted PGx implementation program, including descriptions of our interventions, the critical challenges faced, and the major program successes. By describing our experience, we aim to assist other clinical teams in achieving sustainable PGx implementation in their health systems.

24 June 2023 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
AGAndrea Gaedigk
Andrea Gaedigk
EBErin C. Boone
Erin C. Boone
ATAmy J. Turner
Amy J. Turner
RSRon H.N. van Schaik
Ron H.N. van Schaik
DCDilyara Chernova
Dilyara Chernova
LKLisa V. Kalman
Lisa V. Kalman

21 April 2026 in Histopathology
Verified
Journal Article
Open access
PDF file
CQCecily M Quinn
Cecily M Quinn
PTPuay Hoon Tan
Puay Hoon Tan
KAKimberly H Allison
Kimberly H Allison
EBEdi Brogi
Edi Brogi
SLSunil Lakhani
Sunil Lakhani
WBWCT Standing Editorial Board
WCT Standing Editorial Board
The 6th edition of the WHO Classification of Breast Tumours introduces both major and minor changes based on recent advances in our understanding of breast biology, developments in diagnostic modalities, identification of specific molecular targets and new treatment regimens necessitating modifications to pathology reporting and tumour biomarker categorisation. This review summarises the main changes that strive towards a classification of global relevance. In invasive carcinoma, predictive factors increasingly inform modern breast cancer treatment. The 6th edition provides an update on HER2 reporting categories following the DESTINY‐Breast 04 and 06 trials. Terminologies used to classify invasive tumours are clarified, with the term ‘variant’ now reserved for molecular/genetic alterations. Invasive lobular carcinoma (ILC) with extracellular mucin is recognised as a new diagnostic entity with prognostic implications. The diagnosis of mucinous carcinoma (MC) is reserved for mucin secreting carcinomas with grade 1 or 2 morphology and a favourable biomarker profile. The diagnosis of malignant phyllodes tumours requires only four of the original five adverse histological criteria. Classification of neuroendocrine tumours (NETs) is revised, recognising that the unified model, promoted in the 5th edition, is difficult to apply to the breast. New approaches to the classification of adenomyoepithelioma are discussed but the 5th edition system is broadly retained. A new section on ‘Small Diagnostic Samples’ outlines the merits of non‐operative biopsy diagnosis, the B coding system and the importance of multidisciplinary review. Changes to diagnostic practice and the emerging role of artificial intelligence, with advantages and challenges, are discussed in a new section on ‘Digital Pathology’.